Autumn 2025
AI. Longevity. Revolution
Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China have taken the lead in this area, but Europe should gear up.
By combining the pattern recognition capabilities of artificial intelligence (AI) with biological maps of the ageing process, it may be possible to slow down or even reverse the molecular processes of ageing. Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China have taken the lead in this area, but Europe should gear up.
Further topics in this issue:
- Biotech, key to Europe’s strategic autonomy – Ion Arocena, CEO of ASEBIO
- EU bets on biotech: Up 32% through new funds – during the summer break, the European Commission unveiled a €10bn Life Sciences Strategy.
- Food biotech: EASAC sees immediate need for action
- Novo Nordisk: ups and downs – and ups again
- Stock Market: European Biotech back on stage
- Bioanalytics – From Method Validation to the Life-Cycle
- Value chain disruption – The geopolitics steering biotech
- Regulation: US-policy-made challenges for the biopharma-sector
- Cell therapeutics – Solid tumours meet their match – Interview T-with Thomas Soloway and – Dr Elisa Kieback from T-knife
- BioSpain 2025 breaks visitor records
- Science & Technology – Oncology: cytokines for NK cell activation/New compound reverses asthma/Unmasking CAR-T haematotocicity
- Biopeople; update clinical trials; News from SLAS, BIOTECH Austria, YEBN, ELRIG
- Special: CROs & CDMOs
- New: Cluster Focus – bioRN cluster, Germany
- Focus AI in Life Sciences
